Korean stem cell hospitals and centres: service menus, programme details and price ranges.
Full provider and organisation profiles — services, pricing, medical team and outcomes.
EHL Bio Hospital (㈜이에이치엘바이오) is a Korean hospital specialising in adult stem cell therapy, founded in 2012. What sets it apart from ordinary stem cell clinics is that the hospital runs its own research institute in Uiwang, Gyeonggi-do and its own international-standard laboratories: two in-house GMP plants culturing more than 6,000 lots a year in CLASS 100 clean rooms, inspected by Korea's MFDS and holding a CPC licence from Japan's Ministry of Health, Labour and Welfare. Patient care centres on the EHL Cell Center at 136 Apgujeong-ro in Gangnam, Seoul. Core technology is autologous adipose-derived stem cells, behind a four-drug pipeline: ADSTEM for atopic dermatitis (Phase 3 IND filed in 2024), KDSTEM for chronic kidney disease (Phase 1 from 2023), RASTEM for rheumatoid arthritis (preparing Phase 1) and PDSTEM for Parkinson's disease (preclinical). It also produces EHL-STEM conditioned media with an internationally registered INCI name, works on NK, T, dendritic and iNKT immune cells and exosomes, and publishes 11 patent filings, alongside a network of roughly 100 partner hospitals in Korea and 50 overseas.
View profile
Cheongdam The Cell (Cheongdam Stem Cell) is an autologous adipose stem-cell hospital in Busan, South Korea. It isolates SVF from the patient's own fat with HuriCell®, Hurim BioCell's closed automated system, and counts every batch on a SOL COUNT analyser. Packages start at KRW 4,000,000, with the 70–100 million-cell body + face programme at KRW 15,000,000 (regular KRW 20,000,000). Treatment is same-day.
View profile
Cheongdam Cell Clinic (청담셀의원) is a stem cell and anti-ageing clinic on the 15th floor of SB Tower on Dosan-daero in Gangnam, Seoul. Its stated approach avoids cell cultivation: bone marrow is harvested, highly concentrated cells are isolated and reinjected, all within a single half-day. Five goal-based programmes are offered — 淸Cell for whole-body rejuvenation, 性Cell for sexual function, 美Cell for skin, 毛Cell for hair and 活Cell for chronic pain — led by Dr. Jo Chan Ho, an attending professor at Hanyang University and a director of the Korean Association of Stem Cell Therapy.
View profile
Bong Bong (봉봉성형외과) is a plastic surgery hospital and wellness clinic in Gangnam, Seoul that extended from surgery into anti-ageing through its Basic Cell programme. It runs its own cell laboratory, uses a blood-based cell kit so treatment finishes the same day, delivers around 100 million cells per session, cites more than 2,000 clinical cases, and surrounds the therapy with six supporting programmes including hyperbaric oxygen, whole-body lymphatic care and IV nutrient therapy.
View profile
Banobagi Plastic Surgery (바노바기성형외과) in Gangnam, Seoul, offers SVF therapy — stromal vascular fraction. The patient's own blood, fat and bone marrow are processed into a five-part cell preparation: SVF cells, growth factors, SDF-1α, white blood cells and platelets. It is then returned to the body for skin repair, anti-ageing, immune support and scar treatment. The published protocol runs in four steps, with cells prepared inside the hospital's own one-stop sterile cabinet. Banobagi reports a survival rate of 96.7 ± 2.32% for blood-derived SVF and 90.73 ± 2.35% for bone-marrow-derived SVF.
View profile
Lienjang (리엔장성형외과) is a plastic surgery hospital in Gangnam, Seoul, on floors 14–18 of 343 Gangnam Tower by exit 10 of Gangnam Station, with a dedicated Thai-language site and staff. Its stem cell menu has two programmes: facial stem cell injection and an intravenous stem cell drip. Both use non-cultured adult stem cells isolated from the patient's own blood, so the draw and reinjection happen the same day. A specialist anaesthesiologist is on staff and the clinic runs a signature aftercare programme called Inner Beauty.
View profile
Wonjin (원진성형외과) is a plastic surgery hospital in Gangnam, Seoul, with a dedicated Thai-language site. Its anti-ageing menu includes a stem cell procedure using adult stem cells from the patient's own body: about 1–2 hours, no suture removal, no hospitalisation, numbing cream with sedation, and one day in Korea recommended. The harvested cells are applied three ways — stem cell fat grafting, facial skin rejuvenation and SmartPrep2 hair growth.
View profileCell therapy manufacturer hub
The Korean stem cell R&D and manufacturing company behind cell therapy at roughly 100 partner hospitals — read its drug pipeline, GMP plants, licences and patents.
Open the full EHL Bio profile20 articles built from Cheongdam The Cell's own data — filter further by topic or disease group.
Same-day autologous SVF from your own fat, focused on recovery and healthy aging.
View hospital profile
EHL BioEHL Bio is a Korean stem cell medical group that combines three things: a treating hospital, a bio research institute founded in 2012, and its own international-standard GMP laboratory able to culture over 6,000 cell lots per year. Its edge is proprietary technology for isolating and expanding a patient's own adipose-derived stem cells, plus a clinical pipeline of cell drugs including ADSTEM, KDSTEM, RASTEM and PDSTEM.
GMP (Good Manufacturing Practice) is the regulator-defined manufacturing standard that keeps every production lot consistent. EHL Bio's first GMP centre was completed in 2015, inspected by Korea's MFDS in 2016, and a second centre opened in 2019, giving a combined 6,000 lots per year. Inside are particle-, temperature- and humidity-controlled cleanrooms, with all cell handling done in biological safety cabinets (BSC).
Adipose-derived stem cells are mesenchymal stem cells (MSCs) isolated from a patient's own fat. They self-renew and can differentiate into bone, cartilage, muscle and neural lineages — but their bigger clinical value is immunomodulation and anti-inflammatory signalling, the main mechanism behind their use in chronic disease. Korea favours fat as the source because harvesting is simple, cell yield per gram is high, and autologous cells avoid rejection issues.
ADSTEM inj. is EHL Bio's cell drug using the patient's own adipose-derived mesenchymal stem cells, given as two intravenous infusions, targeting moderate-to-severe subacute and chronic atopic dermatitis. Phase 1 finished in 2017 and the product was approved into phase 2, run at Chung-Ang University Hospital and five other sites.
KDSTEM inj. is EHL Bio's cell therapy candidate using the patient's own urine-derived mesenchymal stem cells, given as repeat intravenous infusions for chronic kidney disease. Its scientific hook is that these cells express Klotho, an anti-ageing protein with antioxidant, anti-senescence, angiogenic and metabolic-regulating roles. It sits in preclinical and early clinical development.
RASTEM inj. is EHL Bio's autologous adipose MSC therapy, given as repeat intravenous infusions for moderate-to-severe rheumatoid arthritis. Preclinical work is complete and phase 1 preparation is under way. The concept is to use MSC immunomodulation to reduce autoimmune joint destruction.
PDSTEM inj. is EHL Bio's cell therapy candidate for Parkinson's disease, using the patient's own adipose MSCs by repeat intravenous infusion. It is currently in non-clinical study. The rationale is neuroprotection and reduced neuroinflammation rather than direct transplantation of dopaminergic cells as in embryonic stem cell research.
KEYCELL-IM inj. is EHL Bio's immune cell therapy: NK, T, dendritic and iNKT cells are separated from the patient's own blood, each activated and expanded with proprietary culture technology, cryopreserved, then expanded for infusion. Its selling point is that a single apheresis collection yields roughly 30 times more cells than a standard blood draw, enough for 6-12 doses.
Exosomes are nanovesicles every cell releases to signal to others, carrying proteins, lipids and small genetic material. EHL Bio is developing exosomes from adipose mesenchymal stem cells, with neuropathic pain as the lead indication, currently in animal studies supporting patent filings. Additional targets under study include cartilage regeneration, wound healing, diabetes, retinopathy and brain disorders.
Stem cell conditioned media is the fluid produced while culturing stem cells, containing growth factors, cytokines, fibronectin and collagen. EHL Bio's EHL-Stem is INCI-registered as Human Adipose Stromal Cell Conditioned Media. Independent laboratory testing (Dermapro, January 2016) reported a 49% reduction in melanin production, 45% inhibition of tyrosinase and roughly a 9-fold increase in intracellular collagen synthesis.
Alzheimer's damages the memory-controlling hippocampus and language cortex, with amyloid plaque a central driver. No drug fully dissolves plaque today, but stem cells have been reported to reduce amyloid in animal models. The work EHL Bio cites gave 13 stem cell doses to Tg2576 mice and, on the Morris water maze, found cognitive and physical function improved by 23.4% with a 31.3% increase in lifespan.
Osteoarthritis is wear of the joint cartilage leading to inflammation, pain and restricted movement. The cell approach EHL Bio describes is harvesting the patient's own fat, expanding stem cells in the lab, then injecting selected high-quality cells into the affected joint to stimulate cartilage regeneration and reduce inflammation without joint replacement surgery. Results, though, depend heavily on how advanced the degeneration is.
EHL BioEHL Bio publishes a case example where glucose fell from 300 to 120 mg/dL and HbA1c (NGSP) from 10.8% to 6.3% after stem cell treatment. The numbers are striking but they are single-case data, not a randomised controlled trial. The scientific rationale is that MSCs reduce chronic inflammation and insulin resistance, rather than fully regenerating beta cells.
Diabetic foot ulcers are notoriously hard to heal, prone to spreading infection and sepsis, and in severe cases lead to toe or ankle amputation. EHL Bio reports using stem cells to help ulcers close and preserve foot function, showing wound progression before treatment and after the 1st, 2nd and 5th doses. The proposed mechanism is new capillary formation plus reduced chronic inflammation in the wound bed.
Cirrhosis replaces functioning liver tissue with fibrosis. The approach EHL Bio describes uses the patient's own multipotent stem cells injected directly into the hepatic artery so they can support regeneration of damaged liver tissue, with reported reductions in ascites volume and improved liver function. Using autologous cells also lowers immune rejection risk.
A myocardial infarction occurs when a coronary artery blocks and heart muscle loses blood supply. The cell approach EHL Bio describes uses adult stem cells to stimulate vascular regeneration around the blockage, improving perfusion. This field began after Asahara's 1997 discovery of endothelial progenitor cells and clinical trials have expanded since, but it is not standard care in place of revascularisation.
Chronic lung diseases such as emphysema and pulmonary fibrosis permanently damage alveoli and cut gas exchange. EHL Bio lists lung disease among conditions where stem cells hold potential, since MSCs are anti-inflammatory and anti-fibrotic. Human data, however, remain limited to small studies, so core treatment is still smoking cessation, inhaled bronchodilators, pulmonary rehabilitation and oxygen therapy where indicated.
There are over 100 autoimmune diseases, arising when the Th1/Th2 T-cell balance breaks and immunity attacks the body's own tissue. EHL Bio explains that stem cells help restore Th1/Th2 equilibrium, giving them potential in this disease group, and that they normalise both under- and over-active immunity. That is why cell therapy is being trialled across conditions from atopic dermatitis to rheumatoid arthritis.
Most erectile dysfunction is vascular in origin: when penile vessels lose elasticity, blood escapes and erection cannot be sustained. The approach EHL Bio cites injects the patient's own abdominal fat-derived mesenchymal stem cells into the corpus cavernosum. The referenced study (Urology 2018;121:203.e6-203.e13) reported that six months after a single injection, participants' IIEF scores rose from about 6 to about 12 — moving from severe to mild-moderate dysfunction.
EHL Bio publishes its patent and research list to demonstrate technical capability, spanning a fat harvesting/SVF separation kit, 15-PGDH inhibitor applications for atopic dermatitis and rheumatoid arthritis, and a three-dimensional low-oxygen culture method for producing conditioned media. The key distinction for readers: a patent protects an invention; it does not mean the product's efficacy is proven or that it is approved for treatment.
EHL BioEHL Bio began with a bio research institute founded in 2012, then built its own GMP cell-manufacturing centre, earned a Japanese CPC licence, grew a network of roughly 100 partner hospitals in Korea and 50 abroad, and pushed several cell drugs into clinical trials.
Before a lot is released, a GMP lab must test at least four things: sterility, mycoplasma, endotoxin, and the cells themselves — viability, cell count and the surface markers confirming they really are MSCs. These certificates are documents a patient is entitled to ask for.
For Thai patients, treatment at EHL Bio usually means two trips: the first for assessment and fat harvesting, then roughly 4-6 weeks of culture, then a second trip for the infusions. Recent blood work and imaging must be reviewed by the medical team before any booking.
ADSTEM inj. is EHL Bio's adipose stem cell drug for severe atopic dermatitis. Phase 1 focuses on safety and tolerated dose; phase 2 starts measuring efficacy such as eczema severity scores and itch. A phase 2 signal is not the same as approval for general use.
Urine-derived MSCs are cells shed from the urinary tract lining that can be expanded in culture. They are collected without surgery or a tissue biopsy and originate close to the renal system. EHL Bio's KDSTEM Inj. uses them for chronic renal failure, with a mechanism linked to the Klotho protein.
Biologics in rheumatoid arthritis block a specific inflammatory signal such as TNF-alpha or IL-6. RASTEM, a cell drug in EHL Bio's pipeline, instead aims to modulate immune balance through the factors the cells secrete. The two are not interchangeable, and both belong under a rheumatologist's care.
PDSTEM is EHL Bio's pipeline cell drug aimed at Parkinson's disease. Neurodegeneration is hard because dead neurons do not regrow and therapies must cross the blood-brain barrier, so cell approaches focus on calming neuroinflammation and protecting surviving neurons rather than replacing lost ones.
Long-term stem cell storage uses liquid nitrogen at about -196C together with a cryoprotectant such as DMSO and a controlled-rate freeze. The step that most affects final quality is thawing, which must be fast and followed by correct removal of the cryoprotectant.
EHL BioSVF (stromal vascular fraction) is a mixed cell population separated from fat within a single day, containing only a modest share of stem cells. Cultured therapy instead selects and expands MSCs in a lab over 4-6 weeks, giving far higher cell numbers and fuller quality testing, at the cost of time and money.
Each time cells are moved to fresh culture vessels counts as one passage. The higher the passage, the closer cells drift to senescence: slower division and weaker secretion of therapeutic factors. Good labs therefore cap passage number and test potency per lot rather than counting cells alone.
After a stroke the brain's capacity to rewire peaks in the first 3-6 months, and structured rehabilitation remains the best-evidenced treatment. Cell therapy sits at the research stage, with the hope of reducing inflammation and encouraging new blood vessel growth around the damaged area.
Spinal cord injury produces a glial scar that physically and chemically blocks nerve regrowth. Cell research therefore aims to lower inflammation, limit fibrosis and create a more permissive environment for connections — not to splice severed nerves. It remains investigational and case-by-case.
Diabetic peripheral neuropathy comes from chronic high glucose damaging both nerves and the microvessels that feed them. The cell therapy rationale is to promote new capillaries and reduce inflammation, which may ease numbness and burning in some patients — but glucose control remains the decisive factor.
Non-alcoholic fatty liver disease can progress to steatohepatitis, fibrosis and eventually cirrhosis. Losing 7-10% of body weight remains the best-evidenced intervention; stem cell work targets inflammation and fibrosis in liver tissue and is not a substitute for lifestyle change.
Heart failure means the heart cannot pump enough for the body's needs, commonly graded by ejection fraction. Cell research targets myocardial fibrosis and new capillary growth; reported gains tend to be in six-minute walk distance and quality of life rather than large EF jumps.
Type 1 diabetes is autoimmune destruction of pancreatic beta cells; type 2 combines insulin resistance with declining beta-cell function. The cell therapy goals differ accordingly: immune modulation and protection of residual beta cells in type 1, versus lowering inflammation and improving insulin sensitivity in type 2.
Metabolic syndrome is a cluster — excess waist circumference, high blood pressure, high triglycerides, low HDL and elevated glucose — with insulin resistance at its centre. The MSC rationale is to reduce the chronic inflammation linking them, always alongside weight loss and exercise.
A chronic wound is one that has not healed in 4-6 weeks, usually because of poor perfusion, infection or stalled inflammation. Exosomes and stem cell secreted factors carry growth signals that encourage capillary and collagen formation — but only alongside standard wound care.
Lupus is an autoimmune disease that can affect skin, joints, kidneys and blood. Mainstay therapy is immunomodulators and steroids scaled to severity. MSC research focuses on patients refractory to standard treatment, aiming to expand regulatory immune cells and calm inflammation.
Psoriasis arises when immune signalling drives skin cells to divide far too fast, producing thick scaly plaques. A share of patients also develop arthritis, and metabolic risk runs higher than average. The cell therapy idea is systemic immune rebalancing rather than treating skin alone.
Crohn's disease and ulcerative colitis involve immune-driven gut inflammation interacting with the microbiome. The best-supported MSC use is local injection for perianal fistulas in Crohn's — a complication that responds poorly to standard treatment.
EHL BioClinic 'male vitality' packages often bundle stem cells, IV vitamins and hormones. The first step is finding the real cause of the fatigue — low testosterone, sleep apnoea, anaemia, thyroid disease or diabetes — because each has a specific treatment that works better.
Male pattern hair loss is driven by DHT progressively miniaturising follicles. The best-evidenced treatments are minoxidil and 5-alpha reductase inhibitors. Exosomes and stem cell factors are adjuncts that may improve density in some patients but do not stop the hormonal mechanism.
Roughly half of male infertility has a correctable cause: varicocele, infection, hormonal disorders, heat exposure and habits such as smoking. Stem cell research here is early stage and not standard care, so a proper cause workup always comes first.
Testosterone declines slowly with age, roughly 1% per year after 30. Symptoms such as fatigue, lower libido and muscle loss are non-specific, so at least two morning blood tests are needed before concluding anything. Hormone therapy has both benefits and risks that must be weighed with a physician.
SVF (Stromal Vascular Fraction) is a mixed cell population freshly isolated from your own fat: roughly 30% adipose-derived stem cells, 25% immune cells, 20% fibroblasts, 15% pericytes and 10% endothelial progenitors. Cheongdam The Cell builds its stem cell recovery programmes on SVF because those five populations calm inflammation, repair tissue and restore microvasculature at the same time.
HuriCell is a patented, closed-loop automated system for isolating SVF, and it is the technical core of Cheongdam The Cell's regenerative programmes. The workflow has four steps: harvest fat under local anaesthesia, digest the tissue with collagenase, isolate SVF in the automated device, then inject the cells into the target area. A closed system lowers contamination risk and makes cell quality more consistent than manual preparation.
Fat tissue contains roughly 2.0% stem cells versus about 0.002% in bone marrow — a thousandfold difference. That density is the main reason Cheongdam The Cell bases its regenerative programmes on adipose-derived cells. Fat is also harvested under local anaesthesia with less pain and faster recovery, and being autologous it carries no rejection risk.
SVF is a same-day, multi-cell isolate from fat. Cultured MSC means selecting mesenchymal stem cells and expanding them in a lab for 3–6 weeks into a large, pure population. Cheongdam The Cell's core programmes use SVF because they finish in one trip and sit within minimally manipulated autologous use, whereas cultured MSC suits cases needing very high cell doses and repeat infusions, at the cost of waiting time and stricter rules.
Cheongdam The Cell quotes explicit cell numbers: 10–15 million for a full-face injection and 70–100 million for the systemic-plus-facial programme. Those figures describe the SVF actually isolated and measured on an SOL counter before injection. Counting is what turns a package name into something a patient can verify.
Intravenous stem cell recovery delivers autologous SVF into the bloodstream so cells circulate to inflamed tissue and release signalling factors that help rebalance immunity. Cheongdam The Cell positions this within its cellular-health track. It suits people with chronic fatigue or slow recovery, but not those in active cancer treatment, with acute infection, or who are pregnant.
Cellular anti-ageing aims to reduce chronic inflammation, restore microcirculation and stimulate collagen from within — unlike fillers or botulinum toxin, which change appearance directly. Cheongdam The Cell places Healthy Aging as the second stage of its Wellness Journey after cellular health, combining SVF with adjuncts such as an oxygen chamber, light therapy and whole-body cryotherapy.
Cheongdam The Cell's SVF skin programme injects autologous adipose cells into the dermis to stimulate fibroblasts, rebuild collagen and restore microcirculation. The best-supported goals are overall skin quality, elasticity, shallow acne scarring and skin damaged by burns or psoriasis; deep ice-pick scars usually still need laser or other procedures alongside.
Cheongdam The CellThe SVF scalp programme injects autologous adipose cells into the scalp to improve perifollicular circulation, reduce inflammation and extend the growth phase. The centre's medical director published SVF hair-loss research in Stem Cell Research & Therapy in 2021. Responders are typically early-to-moderate thinning with follicles still present — not fully bald areas.
Intra-articular SVF aims to calm synovial inflammation, relieve pain and slow cartilage loss. Most likely to benefit are early to moderate osteoarthritis (Kellgren-Lawrence grade 2–3) with joint space remaining. In advanced bone-on-bone disease, knee replacement remains the clearly superior standard.
Diabetic foot ulcers heal slowly because of microvascular damage, neuropathy and chronic inflammation. Peri-wound SVF aims to promote new vessel formation and reduce inflammation so tissue receives more oxygen. Cheongdam The Cell groups this in its medical track alongside arthritis — but glucose control, offloading and standard wound care remain the non-negotiable base.
Cheongdam The CellThe post-surgical SVF track addresses tissue ischaemia after an operation, partial necrosis, and scarring or contour irregularity after aesthetic surgery, using autologous adipose cells to stimulate capillary formation and improve tissue quality. Cheongdam The Cell lists post-surgical necrosis care explicitly — and it should be planned together with the original surgeon.
Cheongdam The CellCheongdam The Cell's men's programme targets whole-body recovery: energy, sleep quality, post-exercise recovery and the vascular health behind sexual performance, mainly by reducing chronic inflammation and restoring microcirculation. Before starting, check testosterone, glucose, lipids and sleep apnoea — the most common causes respond to basic treatment.
Cheongdam The CellCheongdam The Cell's women's track focuses on whole-body recovery during hormonal transition. The most direct goals are skin quality, tissue elasticity, energy and recovery from fatigue. Menopausal symptoms such as hot flushes and bone loss still need gynaecological assessment and standard management — hormone therapy or bone care — as the primary route.
Cheongdam The CellSVF for muscle recovery aims to reduce post-exertion inflammation, improve perfusion in injured tissue and support tendon and muscle repair. Cheongdam The Cell places this in its regenerative recovery track alongside physiotherapy and adjuncts such as the oxygen chamber and cryotherapy. Realistic expectations are faster recovery and less pain — not performance beyond an athlete's baseline.
Cell banking stores your own adipose-derived stem cells in liquid nitrogen at -196°C so they can be used later without a new harvest each time. Cheongdam The Cell describes four steps: a ~30-minute fat collection, HuriCell SVF isolation, cryopreservation, and thawing for future use. The main reason people bank is that cell quality declines with age.
HemaPure is a blood purification programme listed by Cheongdam The Cell in its recovery track, promoted on the site at 3,500,000 KRW from a list price of 4,500,000 KRW. The idea is to reduce circulating waste and excess lipids alongside a stem cell recovery programme. Anyone interested should request the exact method, the before-and-after markers used, and clear medical indications first.
Cheongdam The Cell organises its services as a six-stage journey: cellular health, healthy aging, recovery, body, beauty and wellness. Stem cell therapy is the backbone, supported by HemaPure, a whole-body oxygen chamber, SunBeam light therapy, a cryo chamber, Korean medicine and physiotherapy. The intent is that international patients can complete several goals in one trip, starting from a medical assessment.
In South Korea, minimally manipulated autologous cells — such as SVF isolated from fat and reinjected the same day — may be used at a physician's discretion within the relevant legal framework, while expanded cell products fall under stricter product regulation. Cheongdam The Cell states that it follows protocols aligned with MFDS guidance and uses the closed HuriCell system to reduce contamination risk.
Cheongdam The Cell is located in Busan, South Korea, and publishes package prices for autologous adipose stem cells: the systemic-plus-facial programme at 70–100 million cells is promoted at 15,000,000 KRW from a 20,000,000 KRW list price, and a full-face programme at 10–15 million cells is 5,900,000 KRW. Thai patients should budget the total cost including flights, accommodation, interpreting and follow-up back home.
Each provider uses a different technique — cultured MSC targets chronic disease, while autologous SVF focuses on recovery in a single day.
Cultured MSC therapy from a GMP Class 100 facility, focused on chronic disease.
Same-day autologous SVF from your own fat, focused on recovery and healthy aging.
Explainers, comparisons and guides for this category — not provider profiles.
Typically 3–5 days covers assessment, harvest, cell delivery and a first review before flying home.
Stem cellCheongdam The Cell prices and a Thai patient's travel guide to BusanThe centre operates a LINE consultation channel for Thai-speaking patients; confirm interpreting on procedure day in advance so risk explanation and consent are clear.
Stem cellCheongdam The Cell prices and a Thai patient's travel guide to BusanAsk for a written breakdown before paying — especially harvest, medication, blood work and follow-up, since inclusions differ between centres.
Stem cellCheongdam The Cell prices and a Thai patient's travel guide to BusanMost are local effects from the harvest and injection — pain, swelling, bruising — usually settling within days. Serious events are uncommon but require a follow-up system.
Stem cellIs stem cell therapy legal in Korea? MFDS rules and SVF safetyThere are legal and cold-chain constraints; check with the relevant Thai authorities rather than relying on informal advice.
Stem cellIs stem cell therapy legal in Korea? MFDS rules and SVF safetyA core SVF programme can finish in a few days; if you add several adjuncts, plan for at least 5–7 days so there is recovery time between procedures.
Stem cellThe Cheongdam The Cell Wellness Journey: six stages from cells to beautyPopular questions on Korean surgery, skin clinics, travel, culture and daily life — each with a short, direct answer.